List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9091726/publications.pdf Version: 2024-02-01

		172207	197535
131	3,289	29	49
papers	citations	h-index	g-index
133	133	133	5472
all docs	docs citations	times ranked	citing authors
			0

#	Article	IF	CITATIONS
1	In vitro evidence of the antitumor capacity of <i>Solanaceae</i> and <i>Cucurbitaceae</i> in colon cancer: A systematic review. Critical Reviews in Food Science and Nutrition, 2022, 62, 6293-6314.	5.4	5
2	Electrospraying as a Technique for the Controlled Synthesis of Biocompatible PLGA@Ag2S and PLGA@Ag2S@SPION Nanocarriers with Drug Release Capability. Pharmaceutics, 2022, 14, 214.	2.0	6
3	Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer. BioImpacts, 2022, , .	0.7	1
4	Synthetic Circular miR-21 Sponge as Tool for Lung Cancer Treatment. International Journal of Molecular Sciences, 2022, 23, 2963.	1.8	10
5	In Vivo Nutritional Assessment of the Microalga Nannochloropsis gaditana and Evaluation of the Antioxidant and Antiproliferative Capacity of Its Functional Extracts. Marine Drugs, 2022, 20, 318.	2.2	8
6	The Development of the Bengamides as New Antibiotics against Drug-Resistant Bacteria. Marine Drugs, 2022, 20, 373.	2.2	10
7	Bioavailability and biotransformation of linolenic acid from basil seed oil as a novel source of omega-3 fatty acids tested on a rat experimental model. Food and Function, 2022, 13, 7614-7628.	2.1	3
8	Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes. Biomedicine and Pharmacotherapy, 2021, 133, 111059.	2.5	32
9	Antitumor Effect of the Ethanolic Extract from Seeds of Euphorbia lathyris in Colorectal Cancer. Nutrients, 2021, 13, 566.	1.7	15
10	Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study. Journal of Biosciences, 2021, 46, 1.	0.5	4
11	Anemonia sulcata and Its Symbiont Symbiodinium as a Source of Anti-Tumor and Anti-Oxidant Compounds for Colon Cancer Therapy: A Preliminary In Vitro Study. Biology, 2021, 10, 134.	1.3	5
12	Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Current Neuropharmacology, 2021, 19, 513-537.	1.4	40
13	Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress. Cancers, 2021, 13, 2058.	1.7	26
14	Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer. Journal of Clinical Medicine, 2021, 10, 2248.	1.0	12
15	The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study. Cancers, 2021, 13, 3169.	1.7	10
16	Impact of the Epigenetically Regulated Hoxa-5 Gene in Neural Differentiation from Human Adipose-Derived Stem Cells. Biology, 2021, 10, 802.	1.3	2
17	Antioxidant and antiproliferative potential of ethanolic extracts from Moringa oleifera, Tropaeolum tuberosum and Annona cherimola in colorrectal cancer cells. Biomedicine and Pharmacotherapy, 2021, 143, 112248.	2.5	11
18	Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer. Cancer Gene Therapy, 2020, 27, 657-668.	2.2	12

#	Article	IF	CITATIONS
19	Magnetically active pNIPAM nanosystems as temperature-sensitive biocompatible structures for controlled drug delivery. Artificial Cells, Nanomedicine and Biotechnology, 2020, 48, 1022-1035.	1.9	23
20	Evaluation of Novel Doxorubicin-Loaded Magnetic Wax Nanocomposite Vehicles as Cancer Combinatorial Therapy Agents. Pharmaceutics, 2020, 12, 637.	2.0	6
21	Gemcitabine-Loaded Magnetically Responsive Poly(ε-caprolactone) Nanoparticles against Breast Cancer. Polymers, 2020, 12, 2790.	2.0	17
22	Cancer therapy based on extracellular vesicles as drug delivery vehicles. Journal of Controlled Release, 2020, 327, 296-315.	4.8	47
23	MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression. Journal of Biosciences, 2020, 45, 1.	0.5	3
24	Germination Improves the Polyphenolic Profile and Functional Value of Mung Bean (Vigna radiata L.). Antioxidants, 2020, 9, 746.	2.2	17
25	Bengamide Analogues Show A Potent Antitumor Activity against Colon Cancer Cells: A Preliminary Study. Marine Drugs, 2020, 18, 240.	2.2	5
26	Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents. AAPS PharmSciTech, 2020, 21, 178.	1.5	33
27	Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer. Pharmaceutics, 2020, 12, 589.	2.0	28
28	Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Cancers, 2020, 12, 1002.	1.7	21
29	Differentiation of Human Mesenchymal Stem Cells towards Neuronal Lineage: Clinical Trials in Nervous System Disorders. Biomolecules and Therapeutics, 2020, 28, 34-44.	1.1	75
30	Nanomedicine in Pancreatic Cancer: A New Hope for Treatment. Current Drug Targets, 2020, 21, 1580-1592.	1.0	3
31	Oxaliplatin–Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study. Pharmaceutics, 2019, 11, 395.	2.0	28
32	Double origin of the extensor hallucis longus muscle: a case report. Surgical and Radiologic Anatomy, 2019, 41, 1421-1423.	0.6	4
33	Nanoformulations for glioblastoma multiforme: a new hope for treatment. Future Medicinal Chemistry, 2019, 11, 2461-2482.	1.1	21
34	Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. Nanomaterials, 2019, 9, 638.	1.9	293
35	Electrospun Nanofibers: Recent Applications in Drug Delivery and Cancer Therapy. Nanomaterials, 2019, 9, 656.	1.9	110
36	Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Scientific Reports, 2019, 9, 20198.	1.6	39

#	Article	IF	CITATIONS
37	An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders. Expert Opinion on Biological Therapy, 2019, 19, 233-248.	1.4	28
38	A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer. Pharmacological Research, 2019, 141, 451-465.	3.1	39
39	The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biology and Medicine, 2019, 16, 688-699.	1.4	65
40	Nano-engineering of biomedical prednisolone liposomes: evaluation of the cytotoxic effect on human colon carcinoma cell lines. Journal of Pharmacy and Pharmacology, 2018, 70, 488-497.	1.2	4
41	Latest in Vitro and in Vivo Assay, Clinical Trials and Patents in Cancer Treatment using Curcumin: A Literature Review. Nutrition and Cancer, 2018, 70, 569-578.	0.9	51
42	Formulation and in vitro evaluation of magnetoliposomes as a potential nanotool in colorectal cancer therapy. Colloids and Surfaces B: Biointerfaces, 2018, 171, 553-565.	2.5	30
43	Proteomic biomarkers in body fluids associated with pancreatic cancer. Oncotarget, 2018, 9, 16573-16587.	0.8	25
44	Nanoemulsion Strategy for Ursolic and Oleanic Acids Isolates from Plumeria Obtusa Improves Antioxidant and Cytotoxic Activity in Melanoma Cells. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 847-853.	0.9	8
45	Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives. BMB Reports, 2018, 51, 563-571.	1.1	19
46	Paclitaxel-loaded hollow-poly(4-vinylpyridine) nanoparticles enhance drug chemotherapeutic efficacy in lung and breast cancer cell lines. Nano Research, 2017, 10, 856-875.	5.8	22
47	Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. European Journal of Pharmaceutical Sciences, 2017, 102, 24-34.	1.9	49
48	Development and Characterization of Magnetite/Poly(butylcyanoacrylate) Nanoparticles for Magnetic Targeted Delivery of Cancer Drugs. AAPS PharmSciTech, 2017, 18, 3042-3052.	1.5	9
49	Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro. Scientific Reports, 2017, 7, 13506.	1.6	31
50	Development of biomedical 5-fluorouracil nanoplatforms for colon cancer chemotherapy: Influence of process and formulation parameters. International Journal of Pharmaceutics, 2017, 530, 155-164.	2.6	16
51	Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. International Journal of Pharmaceutics, 2017, 516, 61-70.	2.6	110
52	Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study. SLAS Discovery, 2017, 22, 348-359.	1.4	15
53	Nanomedical Platform for Drug Delivery in Cancer. Current Organic Chemistry, 2017, 21, .	0.9	6
54	Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells. Archives of Medical Science, 2016, 5, 919-927.	0.4	12

#	Article	IF	CITATIONS
55	Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology, 2016, 50, 836-848.	1.1	11
56	Magnetic solid lipid nanoparticles in hyperthermia against colon cancer. International Journal of Pharmaceutics, 2016, 504, 11-19.	2.6	61
57	Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer. Current Drug Delivery, 2016, 13, 830-838.	0.8	18
58	Specific Colon Cancer Cell Cytotoxicity Induced by Bacteriophage E Gene Expression under Transcriptional Control of Carcinoembryonic Antigen Promoter. International Journal of Molecular Sciences, 2015, 16, 12601-12615.	1.8	14
59	Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles. International Journal of Nanomedicine, 2015, 10, 1291.	3.3	40
60	Enhanced antitumoral activity of doxorubicin against lung cancer cells using biodegradable poly(butylcyanoacrylate) nanoparticles. Drug Design, Development and Therapy, 2015, 9, 6433.	2.0	28
61	Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. PLoS ONE, 2015, 10, e0134111.	1.1	44
62	Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS ONE, 2015, 10, e0140131.	1.1	144
63	Tissue Specific Promoters in Colorectal Cancer. Disease Markers, 2015, 2015, 1-8.	0.6	12
64	Polystyrene nanoparticles facilitate the internalization of impermeable biomolecules in non-tumour and tumour cells from colon epithelium. Journal of Nanoparticle Research, 2015, 17, 1.	0.8	2
65	Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer. AAPS Journal, 2015, 17, 918-929.	2.2	28
66	Transcriptional Profiling of Peripheral Blood in Pancreatic Adenocarcinoma Patients Identifies Diagnostic Biomarkers. Digestive Diseases and Sciences, 2014, 59, 2714-2720.	1.1	41
67	Qualitative and quantitative analyses of anatomists' research: evaluation of multidisciplinarity and trends in scientific production. Scientometrics, 2014, 98, 447-456.	1.6	3
68	A Novel Double-Enhanced Suicide Gene Therapy in a Colon Cancer Cell Line Mediated by Gef and Apoptin. BioDrugs, 2014, 28, 63-74.	2.2	7
69	Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2014, 79, 1-12.	2.6	21
70	Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer, 2014, 14, 511.	1.1	28
71	Cancer stem cells and their implication in breast cancer. European Journal of Clinical Investigation, 2014, 44, 678-687.	1.7	40
72	Four accessory (supernumerary) intrathoracic ribs: a case report. Surgical and Radiologic Anatomy, 2013, 35, 627-629.	0.6	3

#	Article	IF	CITATIONS
73	Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance. Cancer Chemotherapy and Pharmacology, 2013, 71, 537-541.	1.1	10
74	RNA Interference in the Treatment of Colon Cancer. BioDrugs, 2013, 27, 317-327.	2.2	14
75	Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity. International Journal of Pharmaceutics, 2013, 443, 103-109.	2.6	36
76	Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 329-338.	2.0	77
77	Regulatory Systems in Bone Marrow for Hematopoietic Stem/Progenitor Cells Mobilization and Homing. BioMed Research International, 2013, 2013, 1-12.	0.9	43
78	Antitumor Properties of Natural Compounds and Related Molecules. Recent Patents on Anti-Cancer Drug Discovery, 2013, 8, 203-215.	0.8	21
79	Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents. Recent Patents on Anti-Cancer Drug Discovery, 2013, 9, 21-34.	0.8	11
80	Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1204-1216.	0.9	30
81	Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure. International Journal of Molecular Sciences, 2012, 13, 16624-16635.	1.8	27
82	Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 1058-1070.	0.9	106
83	New Gene Therapy Strategies for Cancer Treatment: A Review of Recent Patents. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 297-312.	0.8	44
84	How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment. Current Medicinal Chemistry, 2012, 19, 1870-1888.	1.2	10
85	MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. Journal of Translational Medicine, 2012, 10, 250.	1.8	68
86	Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells. Biomedicine and Pharmacotherapy, 2012, 66, 563-567.	2.5	7
87	DNA Methylation Plasticity of Human Adipose-Derived Stem Cells in Lineage Commitment. American Journal of Pathology, 2012, 181, 2079-2093.	1.9	36
88	Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. International Journal of Nanomedicine, 2012, 7, 5793.	3.3	39
89	Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer. Recent Patents on Biomarkers, 2012, 2, 17-28.	0.3	2
90	5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. International Journal of Nanomedicine, 2012, 7, 95.	3.3	34

#	Article	IF	CITATIONS
91	5-Fluorouracil derivatives: a patent review. Expert Opinion on Therapeutic Patents, 2012, 22, 107-123.	2.4	83
92	Drug resistance induced by paclitaxel and carboplatin plasmatic concentrations in lung cancer cell lines Journal of Clinical Oncology, 2012, 30, 97-97.	0.8	2
93	Role of Cancer Stem Cells of Breast, Colon, and Melanoma Tumors in the Response to Antitumor Therapy. , 2012, , 157-171.		1
94	MDR1 gene expression in peripheral blood as a marker of treatment response in lung cancer Journal of Clinical Oncology, 2012, 30, 96-96.	0.8	1
95	Nanomedicine: Application Areas and Development Prospects. International Journal of Molecular Sciences, 2011, 12, 3303-3321.	1.8	135
96	Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells. Biomedicine and Pharmacotherapy, 2011, 65, 260-270.	2.5	12
97	Multidrug resistance and rhabdomyosarcoma (Review). Oncology Reports, 2011, 26, 755-61.	1.2	10
98	E phage gene transfection associated to chemotherapeutic agents increases apoptosis in lung and colon cancer cells. Bioengineered Bugs, 2011, 2, 163-167.	2.0	6
99	gef Gene Expression in MCF-7 Breast Cancer Cells is Associated with a Better Prognosis and Induction of Apoptosis by p53-Mediated Signaling Pathway. International Journal of Molecular Sciences, 2011, 12, 7445-7458.	1.8	6
100	Promotion of human adiposeâ€derived stem cell proliferation mediated by exogenous nucleosides. Cell Biology International, 2010, 34, 917-924.	1.4	14
101	E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents. International Journal of Oncology, 2010, 37, 1503-14.	1.4	7
102	Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells. Cancer Chemotherapy and Pharmacology, 2010, 66, 69-78.	1.1	22
103	Regression of established subcutaneous B16â€F10 murine melanoma tumors after <i>gef</i> gene therapy associated with the mitochondrial apoptotic pathway. Experimental Dermatology, 2010, 19, 363-371.	1.4	13
104	Differentiation of Intestinal Epithelial Cells Mediated by Cell Confluence and/or Exogenous Nucleoside Supplementation. Cells Tissues Organs, 2010, 191, 478-488.	1.3	14
105	The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo. Journal of Molecular Medicine, 2009, 87, 899-911.	1.7	9
106	Tumour malignancy loss and cell differentiation are associated with induction ofgefgene in human melanoma cells. British Journal of Dermatology, 2008, 159, 370-378.	1.4	11
107	Combined therapy using suicide gef gene and paclitaxel enhances growth inhibition of multicellular tumour spheroids of A-549 human lung cancer cells. International Journal of Oncology, 2008, 33, 121-7.	1.4	8
108	Transfection of MS-36 melanoma cells with gef gene inhibits proliferation and induces modulation of the cell cycle. Cancer Science, 2003, 94, 564-568.	1.7	11

#	Article	IF	CITATIONS
109	Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene. British Journal of Cancer, 2003, 89, 192-198.	2.9	28
110	Contractile Regulatory Proteins Tropomyosin and Troponin-T as Indicators of the Modulatory Role of Retinoic Acid. Cells Tissues Organs, 2003, 175, 25-33.	1.3	2
111	Reverse transcriptase-polymerase chain reaction detection of circulating tumor cells in patients with melanoma: Correlation with clinical stage, tumor thickness and histological type. Pathology International, 2002, 52, 294-299.	0.6	11
112	Modulation of Myogenic Differentiation in a Human Rhabdomyosarcoma Cell Line by a New Derivative of 5-Fluorouracil (QF-3602). Japanese Journal of Cancer Research, 2000, 91, 934-940.	1.7	10
113	Development of Chick Cardiomyocytes: Modulation of Intermediate Filaments by Basic Fibroblast and Platelet-Derived Growth Factors. Cells Tissues Organs, 2000, 167, 163-170.	1.3	8
114	Modulation of α-Actin and α-Actinin Proteins in Cardiomyocytes by Retinoic Acid during Development. Cells Tissues Organs, 1999, 164, 82-89.	1.3	12
115	Multidrug Resistance Phenotype in the RMS-GR Human Rhabdomyosarcoma Cell Line Obtained after Polychemotherapy. Japanese Journal of Cancer Research, 1999, 90, 788-793.	1.7	1
116	GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells. British Journal of Cancer, 1999, 79, 807-813.	2.9	15
117	Characterization of a New Human Embryonal Rhabdomyosarcoma Cell Line, RMS-GR. Japanese Journal of Cancer Research, 1998, 89, 525-532.	1.7	4
118	Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D. , 1998, 75, 379-383.		15
119	Morphometric study of the great arterial trunks and their branches in the human fetal heart with perimembranous ventricular septal defects. Cardiology in the Young, 1997, 7, 50-55.	0.4	0
120	Actinomycin D treatment leads to differentiation and inhibits proliferation in rhabdomyosarcoma cells. Translational Research, 1997, 130, 42-50.	2.4	19
121	Chemical modifications on the acyclic moiety of 3-(2-hydroxyethoxy)-1-alkoxypropyl nucleobases. 2. Differentiation and growth inhibition in rhabdomyosarcoma cells after exposure to a novel 5-fluorouracil acyclonucleoside. Tetrahedron, 1997, 53, 7319-7334.	1.0	21
122	Clinical Significance of Antiheart Antibodies after Myocardial Infarction International Heart Journal, 1997, 38, 779-786.	0.6	11
123	INVERSE EXPRESSION OFmdr 1 AND c-myc GENES IN A RHABDOMYOSARCOMA CELL LINE RESISTANT TO ACTINOMYCIN D. , 1996, 180, 85-89.		17
124	Differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment. Journal of Pathology, 1995, 175, 23-29.	2.1	23
125	Swine Hearts: Quantitative Anatomy of the Right Ventricle. Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia, 1995, 24, 25-27.	0.3	2
126	Circulating α-actin in non-insulin-dependent diabetics with autonomic dysfunction. International Journal of Cardiology, 1995, 51, 127-130.	0.8	4

#	Article	IF	CITATIONS
127	Influence of dimethyl sulphoxide on intermediate filament proteins in human rhabdomyosarcoma cell lines: modulation at subcellular level. The Histochemical Journal, 1994, 26, 519-525.	0.6	8
128	Modulation of contractile proteins in embryonic and fetal chick cardiac cells by phorbol ester, gamma-interferon, 5-azacytidine and diacylglycerols. Life Sciences, 1994, 54, 171-183.	2.0	4
129	Circulating α-Actin in Angina Pectoris. Journal of Molecular and Cellular Cardiology, 1993, 25, 15-22.	0.9	13
130	Expression of epidermal growth factor receptor in chick embryo myocardiocytes: relation with desmin expression during cardiac development. International Journal of Cardiology, 1993, 42, 107-114.	0.8	0
131	Combined therapy using suicide gef gene and paclitaxel enhances growth inhibition of multicellular tumour spheroids of A-549 human lung cancer cells. International Journal of Oncology, 0, , .	1.4	8